Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from WuXi XDC Cayman, Inc. ( (HK:2268) ).
WuXi XDC Cayman Inc., a Hong Kong-listed biopharmaceutical services provider incorporated in the Cayman Islands, specializes in contract development and manufacturing for innovative therapeutics, serving global pharma and biotech customers. Its business model is centered on high-value, technology-intensive services that support clients across multiple stages of drug R&D and production.
The company reported strong annual results for the year ended Dec. 31, 2025, with revenue up 46.7% year-on-year to RMB5.94 billion and gross profit surging 72.5% to RMB2.14 billion, lifting gross margin to 36.0%. Adjusted net profit attributable to shareholders jumped 69.9% to RMB1.56 billion and reported net profit rose to RMB1.48 billion, underscoring improved operating leverage, but the board decided not to recommend a final dividend, signaling a continued focus on reinvestment and internal growth.
The most recent analyst rating on (HK:2268) stock is a Hold with a HK$65.00 price target. To see the full list of analyst forecasts on WuXi XDC Cayman, Inc. stock, see the HK:2268 Stock Forecast page.
More about WuXi XDC Cayman, Inc.
WuXi XDC Cayman Inc., incorporated in the Cayman Islands and listed in Hong Kong, operates in the biopharmaceutical services sector, focusing on contract development and manufacturing services for complex drug modalities. The company targets global pharmaceutical and biotech clients, providing integrated solutions aimed at accelerating drug development and commercialization.
Average Trading Volume: 4,341,532
Technical Sentiment Signal: Sell
Current Market Cap: HK$66.61B
See more data about 2268 stock on TipRanks’ Stock Analysis page.